Revenue Growth, Narrowing Losses and Quarterly Profitability in the Healthcare Business
First written in FY2022-Q3. 8 of 15 entries say "Worsened", first in FY2023-Q2. Latest entry: 2026-08-05.
DeNA moved to the "Worse" side of this theme in 2023.
0 other companies' latest entry also says "Mitigated".
- FY2026-H1MitigatedAnnual report
「Revenue from the Healthcare and Medical business was ¥3,716 million, down 7.9% year on year, while the segment loss was ¥2,327 million, compared with a loss of ¥2,631 million in the same period of the previous year.」
Revenue declined 7.9% year on year, while the segment loss narrowed from ¥2,631 million to ¥2,327 million. - FY2025MitigatedAnnual report
「Revenue from the healthcare and medical business was ¥10,766 million, up 8.1% from the previous consolidated fiscal year, while the segment loss was ¥3,619 million, compared with a loss of ¥3,640 million in the previous consolidated fiscal year.」
Revenue from the Healthcare and Medical business increased 8.1%, while the segment loss narrowed slightly from ¥3,640 million to ¥3,619 million. - FY2025-H1WorsenedAnnual report
「Revenue from the healthcare and medical business was ¥4,032 million, down 4.6% year on year, while the segment loss was ¥2,631 million, compared with a loss of ¥2,206 million in the same period of the previous year.」
Revenue from the healthcare and medical business declined 4.6%, while the segment loss widened from ¥2,206 million in the same period of the previous year to ¥2,631 million. - FY2024WorsenedAnnual report
「Revenue from the healthcare and medical business was ¥9,963 million, up 42.6% from the previous consolidated fiscal year, while the segment loss was ¥3,640 million, compared with a loss of ¥2,202 million in the previous consolidated fiscal year.」
The healthcare and medical business, including データホライゾン and アルム, generated 42.6% revenue growth, while the segment loss widened from ¥2,202 million to ¥3,640 million. - FY2024-Q3WorsenedAnnual report
「Revenue from the healthcare and medical business was ¥6,592 million, up 73.2% year on year, while the segment loss was ¥3,128 million, compared with a loss of ¥1,831 million in the same period of the previous year.」
Revenue from the healthcare and medical business increased substantially, while the segment loss widened from ¥1,831 million in the same period of the previous year to ¥3,128 million. - FY2024-Q2WorsenedAnnual report
「Revenue from the healthcare and medical business was ¥4,226 million, up 133.3% year on year, while the segment loss was ¥2,206 million, compared with a loss of ¥912 million in the same period of the previous year.」
Revenue increased substantially due in part to the consolidation of データホライゾン and アルム as subsidiaries, while the segment loss widened from ¥912 million in the same period of the previous year to ¥2,206 million. - FY2024-Q1WorsenedAnnual report
「Revenue from the healthcare and medical business was ¥1,960 million, up 164.8% year on year, while the segment loss was ¥1,172 million, compared with a loss of ¥212 million in the same period of the previous year.」
Revenue increased substantially as a result of strengthening the business portfolio, including the consolidation of データホライゾン and アルム as subsidiaries, while the segment loss widened from ¥212 million in the same period of the previous year to ¥1,172 million. - FY2023WorsenedAnnual report
「Revenue from the healthcare and medical business was ¥6,985 million, up 132.8% from the previous consolidated fiscal year, while the segment loss was ¥2,202 million, compared with a loss of ¥624 million in the previous consolidated fiscal year.」
Revenue increased substantially following the consolidation of データホライゾン and アルム as subsidiaries, while the segment loss widened from ¥624 million to ¥2,202 million. - FY2023-Q3WorsenedAnnual report
「Revenue from the healthcare and medical business was ¥3,807 million, up 78.4% year on year, while the segment loss was ¥1,831 million, compared with a loss of ¥421 million in the same period of the previous year.」
Revenue from the healthcare and medical business increased due in part to the consolidation of subsidiaries, while the segment loss widened from ¥421 million in the same period of the previous year to ¥1,831 million. - FY2023-Q2WorsenedAnnual report
「Revenue from the healthcare and medical business was ¥1,811 million, up 68.5% year on year, while the segment loss was ¥912 million, compared with a loss of ¥534 million in the same period of the previous year.」
Revenue from the healthcare and medical business increased 68.5%, while the segment loss widened from ¥534 million in the same period of the previous year to ¥912 million. - FY2023-Q1AdvancedAnnual report
「Revenue from the healthcare business was ¥740 million, up 75.5% year on year, while the segment loss was ¥212 million, compared with a loss of ¥379 million in the same period of the previous year.」
Revenue from the healthcare business increased 75.5% year on year, while the segment loss narrowed from ¥379 million to ¥212 million. - FY2022AdvancedAnnual report
「Revenue from the healthcare business was ¥3,000 million, up 42.9% from the previous consolidated fiscal year, while the segment loss was ¥624 million, compared with a loss of ¥1,194 million in the previous consolidated fiscal year.」
The healthcare business generated 42.9% revenue growth for the full fiscal year, while the segment loss narrowed from ¥1,194 million to ¥624 million. - FY2022-Q3First statedAnnual report
「Revenue from the healthcare business was ¥2,134 million, up 41.4% year on year, while the segment loss was ¥421 million, compared with a loss of ¥943 million in the same period of the previous year. The healthcare services business, including 「kencom」, performed steadily, and despite making upfront investments for the future, the segment was profitable in the third quarter.」
Although the healthcare business recorded a cumulative segment loss of ¥421 million, revenue increased 41.4% year on year and the loss narrowed. It was disclosed for the first time that the segment was profitable in the third quarter.